• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody.

作者信息

Krueger James G, Kim Brian S, Weidinger Stephan, Kataoka Yoko, O'Malley John T, Yen Karl, Van Krinks Cassie, Vela Jose

机构信息

Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

Acta Derm Venereol. 2025 Aug 18;105:adv43608. doi: 10.2340/actadv.v105.43608.

DOI:10.2340/actadv.v105.43608
PMID:40824160
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12376381/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3699/12376381/246ef88300be/ActaDV-105-43608-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3699/12376381/c11bf66a84bf/ActaDV-105-43608-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3699/12376381/246ef88300be/ActaDV-105-43608-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3699/12376381/c11bf66a84bf/ActaDV-105-43608-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3699/12376381/246ef88300be/ActaDV-105-43608-g002.jpg

相似文献

1
In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody.体外证据表明OX40配体单克隆抗体安米利单抗的非耗竭作用机制
Acta Derm Venereol. 2025 Aug 18;105:adv43608. doi: 10.2340/actadv.v105.43608.
2
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.抗OX40配体抗体amlitelimab用于中重度特应性皮炎患者的2b期随机临床试验。
J Allergy Clin Immunol. 2025 Apr;155(4):1264-1275. doi: 10.1016/j.jaci.2024.10.031. Epub 2024 Nov 8.
3
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.
J Eur Acad Dermatol Venereol. 2025 Jul 24. doi: 10.1111/jdv.20877.
4
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.奥昔利单抗（一种完全人源、非耗竭性、非细胞毒性的 OX40 配体单克隆抗体）治疗特应性皮炎的安全性和有效性：一项 IIa 期随机安慰剂对照试验的结果。
Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240.
5
OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.OX40-OX40L抑制疗法治疗特应性皮炎——聚焦于罗卡替尼单抗和阿利替尼单抗。
Pharmaceutics. 2022 Dec 8;14(12):2753. doi: 10.3390/pharmaceutics14122753.
6
A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab.作为特应性皮炎潜在治疗靶点的OX40-OX40L通路的叙述性综述：聚焦于罗卡替尼单抗和阿利特利单抗。
Dermatol Ther (Heidelb). 2024 Dec;14(12):3197-3210. doi: 10.1007/s13555-024-01308-8. Epub 2024 Nov 20.
7
Exacerbation of Crohn's Disease Following Exposure to Anti-OX40 Monoclonal Antibody Therapy.接触抗OX40单克隆抗体治疗后克罗恩病病情加重
ACG Case Rep J. 2025 Aug 13;12(8):e01810. doi: 10.14309/crj.0000000000001810. eCollection 2025 Aug.
8
Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation of Zr-Ivuxolimab, a Human OX40 PET Tracer.推进T细胞功能的体内检测：人OX40正电子发射断层显像（PET）示踪剂Zr-Ivuxolimab的研发与临床前评估
J Nucl Med. 2025 Jul 24. doi: 10.2967/jnumed.125.269799.
9
OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.皮肤鳞状细胞癌中的OX40+调节性T细胞抑制效应T细胞反应并与转移潜能相关。
Clin Cancer Res. 2016 Aug 15;22(16):4236-48. doi: 10.1158/1078-0432.CCR-15-2614. Epub 2016 Mar 31.
10
Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis.CD30L与OX40L的比较显示CD30L是特应性皮炎中一个有前景的治疗靶点。
Allergy. 2025 Feb;80(2):500-512. doi: 10.1111/all.16412. Epub 2024 Nov 26.

本文引用的文献

1
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.抗OX40配体抗体amlitelimab用于中重度特应性皮炎患者的2b期随机临床试验。
J Allergy Clin Immunol. 2025 Apr;155(4):1264-1275. doi: 10.1016/j.jaci.2024.10.031. Epub 2024 Nov 8.
2
The role of OX40 ligand/OX40 axis signalling in atopic dermatitis.OX40 配体/OX40 轴信号在特应性皮炎中的作用。
Br J Dermatol. 2024 Sep 18;191(4):488-496. doi: 10.1093/bjd/ljae230.
3
An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis.
一个非比寻常的故事：OX40 和 OX40L 在特应性皮炎中的作用。
Cells. 2024 Mar 28;13(7):587. doi: 10.3390/cells13070587.
4
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.OX40抑制剂替雷佐利单抗治疗中度至重度特应性皮炎的2b期随机试验。
J Allergy Clin Immunol Glob. 2023 Nov 22;3(1):100195. doi: 10.1016/j.jacig.2023.100195. eCollection 2024 Feb.
5
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.奥昔利单抗（一种完全人源、非耗竭性、非细胞毒性的 OX40 配体单克隆抗体）治疗特应性皮炎的安全性和有效性：一项 IIa 期随机安慰剂对照试验的结果。
Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240.
6
The unique properties of IgG4 and its roles in health and disease.IgG4 的独特性质及其在健康和疾病中的作用。
Nat Rev Immunol. 2023 Nov;23(11):763-778. doi: 10.1038/s41577-023-00871-z. Epub 2023 Apr 24.
7
Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases.OX40在T细胞上的多样作用作为皮肤病的治疗靶点
J Invest Dermatol. 2023 Apr;143(4):545-553. doi: 10.1016/j.jid.2022.11.009. Epub 2023 Feb 25.
8
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.抗 OX40 抗体治疗中重度特应性皮炎：一项多中心、双盲、安慰剂对照的 2b 期研究。
Lancet. 2023 Jan 21;401(10372):204-214. doi: 10.1016/S0140-6736(22)02037-2. Epub 2022 Dec 9.
9
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.OX40L 抑制抑制健康志愿者 KLH 驱动的免疫反应：一项证明 KY1005 药效学的随机对照试验。
Clin Pharmacol Ther. 2022 May;111(5):1121-1132. doi: 10.1002/cpt.2539. Epub 2022 Mar 1.
10
JAK inhibitors in the treatment of atopic dermatitis.JAK 抑制剂在特应性皮炎治疗中的应用。
J Allergy Clin Immunol. 2021 Oct;148(4):927-940. doi: 10.1016/j.jaci.2021.08.009. Epub 2021 Aug 24.